#USA #New York #Class Action #Securities Fraud #BioAge

Important Notice for BioAge Investors

Levi & Korsinsky, LLP has issued a reminder to shareholders of BioAge Labs, Inc. regarding a crucial lead plaintiff deadline set for March 10, 2025. This announcement pertains to a class action securities lawsuit that aims to recover losses incurred by investors affected by alleged securities fraud associated with BioAge's operations.

Overview of the Lawsuit

The class action lawsuit involves all shareholders who purchased stock based on BioAge's registration statement during their initial public offering on or around September 26, 2024. The complaint stems from BioAge’s announcement made on December 6, 2024, where it disclosed the discontinuation of its STRIDES Phase 2 trial for its primary product candidate, azelaprag, due to safety concerns regarding elevated liver transaminase levels noted in participants. This revelation caught many investors off-guard as only three months prior, during the IPO, BioAge had promoted azelaprag as a promising candidate for use in obesity treatment therapies.

Following this critical announcement, BioAge’s stock dramatically dropped from $20.09 per share to $4.65 per share within a day, resulting in significant financial losses for shareowners.

Your Rights as an Investor

Investors who have suffered losses are encouraged to submit requests to be appointed as lead plaintiffs, with the deadline for such submissions ending on March 10, 2025. Importantly, you can still participate in any potential recovery without the necessity of serving as a lead plaintiff.

No Fees Required

For those class members involved in this action, it is essential to note that compensation may be secured without incurring out-of-pocket costs or fees. Sharing in a recovery does not come with a financial burden or obligation to participate in the lawsuit.

Levi & Korsinsky’s Record

Levi & Korsinsky has built a reputation for effectiveness over the past two decades, having secured hundreds of millions of dollars for investors. The firm has considerable expertise in navigating complex securities litigation and is supported by a dedicated team of over 70 professionals committed to assisting clients. Notably, for seven consecutive years, the firm has been recognized in ISS Securities Class Action Services' Top 50 Report as one of the premier securities litigation firms in the United States.

For individual inquiries regarding your eligibility or for more information, BioAge investors can reach out directly to Levi & Korsinsky’s Joseph E. Levi, Esq. via email or by phone.

Conclusion and Call to Action

If you are an investor who has experienced losses linked to BioAge’s stock, don’t miss the opportunity to assert your rights. The impending deadline is fast approaching, and Levi & Korsinsky is ready to assist you in navigating this process. To receive further details and to get in touch with a member of their team for assistance, please follow the provided link: BioAge Labs Inc. Lawsuit Submission.

This situation illustrates the importance of being aware of your rights as an investor and the resources available to potentially recover losses sustained due to misleading information in security transactions.